Search
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.
T487
go.drugbank.com/drugs/DB05474ExperimentalT487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.
Laronidase
go.drugbank.com/drugs/DB00090ApprovedInvestigationalThe predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.
Dithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnHowever, its use is severely limited due to its toxicity. Dithiazanine iodide was associated with eight fatal cases of severe acidosis and shock between 1961 and 1964.
NCX 1022
go.drugbank.com/drugs/DB05410ExperimentalNCX is an NO-releasing derivative of hydrocortisone.
TB-402
go.drugbank.com/drugs/DB06050InvestigationalIt is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation. … TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood.
Olopatadine
go.drugbank.com/drugs/DB00768Approved[A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.
Products: Olopan 0.1%w/v Eye Drops, PATADAY OPHTHALMIC SOLUTION 0.2%w/vZYC300
go.drugbank.com/drugs/DB04986InvestigationalIt is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
FINLAY-FR-1
go.drugbank.com/drugs/DB16524Experimental, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity
Entecavir
go.drugbank.com/drugs/DB00442ApprovedInvestigationalEntecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine